Warrior Labz SARMS
FDA issued a warning letter to Warrior Labz SARMS (Simi Valley, CA, United States) on Jun 12, 2023. Subject: Unapproved New Drugs, Misbranded.
From the letter: “Your “RAD-140 Testolone,” “MK-677 Ibutamoren,” “MK-2866 Ostarine,” “LGD-4033 Ligandrol,” “19-Nor Andro,” “4-Andro,” “BPC-157,” “TB-500,” “Viagra-Max Sildenafil,” and “Cialis-Max Tadalafil” products are not generally recognized as safe and…”
At a glance
What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.
- Violations
- 1 finding · 1 issue type
- Cited
- No CFR or ISO section
- Response due
- 15 working days after receipt of this letter
- FDA asks for
- 1 actions
- Named as possible actions
- Seizure, injunction
- Issued by
- Center for Drug Evaluation and Research
- Published status
- No close-out recorded
AI assisted findings
Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.
01Registration, listing & premarket · 21 U.S.C. 321(p), 21 U.S.C. 331(d), 21 U.S.C. 355(a)The firm markets unapproved new drugs, including SARMs, peptides, and male enhancement products, with claims for human use, in violation of the FD&C Act.
Your “RAD-140 Testolone,” “MK-677 Ibutamoren,” “MK-2866 Ostarine,” “LGD-4033 Ligandrol,” “19-Nor Andro,” “4-Andro,” “BPC-157,” “TB-500,” “Viagra-Max Sildenafil,” and “Cialis-Max Tadalafil” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
Additional FDA passages
1 extracted findingsSelected FDA passages, not the complete letter.
Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.
What FDA requested
- Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.
FDA Warning Letter
37 paragraphs · 12 sectionsText as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)
RE: 655280
1Introduction
4 paragraphs
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https://warriorlabzsarms.com/ in May 2023 and has observed that you take orders there for products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including “RAD-140 Testolone,” “MK-677 Ibutamoren,” “MK-2866 Ostarine,” and “LGD-4033 Ligandrol.” We observed that you also take orders on your website for “19-Nor Andro,” “4-Andro,” “BPC-157” (injectable and nasal spray), “TB-500” (injectable and nasal spray), “Viagra-Max Sildenafil,” and “Cialis-Max Tadalafil.” We also have reviewed your Instagram social media website at the Internet address https://www.instagram.com/warrior_labz_sarms/?hl=en, which directs consumers to your website https://warriorlabzsarms.com/ to purchase your products. As described below, your before-named products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 301(d).
FDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke. Likewise, FDA has safety concerns about your unapproved new drugs intended for injectable1 and intranasal2 routes of administration.
Despite statements on your product labeling marketing your products for “research purpose only” and “not for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and/or affect the structure or function of the body. Examples of claims observed on your website and social media website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:
From your website https://warriorlabzsarms.com/:
2RAD-140 Testolone
1 paragraph
“RAD-140 / TESTOLONE SARM for Muscle Growth and Size Reduces Fat and Increases Muscle Mass Rapid Muscle Recovery Carries the benefits of Testosterone injections without all the risks Reduced androgenic effects on the prostate to cut the risk of growth of Prostate Cancer. Produces High Stamina and Energy Levels Increased Libido and Sexual Performance . . . CYCLE LENGTH – 12 Weeks is best for optimal results. DOSAGE – 1ML AM”
3MK-677 Ibutamoren
1 paragraph
“MK- 677 – IBUTAMOREN / NUTROBOL Increased Production of GH and IGF-1 Promotes muscle growth Increases bone density Has anti-again [sic] properties Treats deficiency in Growth Hormone Beneficial in preventing muscle wasting . . . DOSAGE – 1ML ABOUT 2-3 HOURS BEFORE BED OR 1ST THING IN THE AM”
4MK-2866 Ostarine
1 paragraph
“OSTARINE / MK-2866 Increases muscle mass, growth, and strength Joint healing capabilities Helps maintain Muscle Mass when calorie deficit Improves and protects Heart Health Builds endurance Accelerates healing . . . CYCLE LENGTH – 12 Weeks is best for optimal results. DOSAGE – 1ML AM”
5LGD-4033 Ligandrol
1 paragraph
“LGD-4033 / LIGANDROL Increased Strength Increased Lean Muscle Mass Faster Muscle Recovery Helps maintain your hard-earned gains Developed to prevent muscle wasting Treats Osteoporosis . . . CYCLE LENGTH – 12 Weeks is best for optimal results. DOSAGE – 1ML AM”
619-Nor Andro
1 paragraph
“19 NOR ANDRO . . . EXTREME LEAN MUSCLE GROWTH SERIOUS STRENGTH GAINS PREVENTS MUSCLE FATIGUE FASTER RECOVERY FROM SORENESS”
74-Andro
1 paragraph
“4-ANDRO . . . EXTREME LEAN MUSCLE GROWTH INCREASES IGF-1 AND GH SECRETION PREVENTS MUSCLE FATIGUE RECOVER FROM SORENESS”
8BPC-157
4 paragraphs
“BPC 157 has been shown to protect organs and aids in the prevention of gastric ulcers. BPC-157 acts systemically in the digestive tract to combat leaky gut, IBS, gastrointestinal cramps, and Crohn’s disease. This peptide has been known to exhibit analgesic characteristics. Research has shown its ability to help skin burns heal at a faster rate by increasing blood flow to damaged tissues. BPC-157 significantly accelerates reticulin and collagen formation as well as angiogenesis together with stimulation of macrophages and fibroblasts infiltration representing a potential therapeutic tool in wound healing management. . . .
Doses can range from 1 mg to 20 mg per week by SQ or IM injections divided into 2-3 injections per week. It is then lowered after the first 1-2 weeks to a maintenance dose approximately 1/2 of the original weekly dose and administered once a week thereafter.”
TB-500 “TB-500 5MG VIAL . . . In animal models, Thymosin Beta-4 has been shown to improve blood vessel growth, regulate wound healing, decrease inflammation, and reduce oxidative damage in the heart and central nervous system. Thymosin-beta-4 has a role in protection, tissue repair, regeneration, and remodeling of injured or damaged tissues. It is also of active interest in anti-aging research. . . .
Doses can range from 1 mg to 20 mg per week by SQ or IM injections divided into 2-3 injections per week. It is then lowered after the first 1-2 weeks to a maintenance dose approximately 1/2 of the original weekly dose and administered once a week thereafter.”
9Viagra-Max Sildenafil
1 paragraph
“Viagra-Max / Sildenafil is usually taken only when needed, generally 30 minutes to 1 hour before desired sexual activity. You may take it up to 4 hours before sexual activity. Do not take Viagra more than once per day. Shake the oral suspension (liquid) before usage [sic]”
10Cialis-Max Tadalafil
5 paragraphs
“Cialis can be taken once a day. If your doctor recommends using Cialis every day, you should take the drug at about the same time each day. You don’t need to take Cialis before sexual activity unless your doctor says to use the drug only as needed.”
From your webpage https://warriorlabzsarms.com/testimonials/:
From a testimonial by John R. – “For almost 4 weeks now I have been using MK-677, RAD-140 and LGD-4033, The Warrior Mass Stack, and I feel amazing. My strength is up and I am putting on muscle size and my sleep at night from the MK-677 is awesome. I feel like a Warrior !!!”
From your Instagram website https://www.instagram.com/warrior_labz_sarms/?hl=en:
From a July 6, 2022 post – “Warrior Labz is proud to offer you a Six Pack !!! Yes...A Strong 6 Pack of any 6 Individual Sarms, Peptides, Pro Hormones, Male Enhancement for only $299 Delivered anywhere USA !!! . . . Stacks are Higher and additional Bottles may be purchased @ $50 each also. Payment via: Zelle, Cash App, Venmo, Apple Pay and Pay Pal - Friends and Family. Call or Text . . . www.warriorlabzsarms.com”
11Unapproved New Drugs
1 paragraph
Your “RAD-140 Testolone,” “MK-677 Ibutamoren,” “MK-2866 Ostarine,” “LGD-4033 Ligandrol,” “19-Nor Andro,” “4-Andro,” “BPC-157,” “TB-500,” “Viagra-Max Sildenafil,” and “Cialis-Max Tadalafil” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
12Conclusion
4 paragraphs
This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.
Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.
Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.
Citations and trends
Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.
This letter cites no 21 CFR section or ISO 13485 clause.
Issue types
Record details
- Issuing center
- Center for Drug Evaluation and Research
- Issuing office
- Center for Drug Evaluation and Research
- Location
- Simi Valley, CA, United States
- Letter posted date
- Jun 20, 2023
- Letter issue date
- Jun 12, 2023
- Addressed to
- Not recorded
- Inspection dates
- Not recorded
- Response window
- 15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations.
- Record length
- 1,561 words · 0 recorded redactions
- Published status
- No published close-out
- Original letter
- View on FDA.gov (opens in a new tab)
- Dataset last checked
- Nov 11, 2026 · How this is built
A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.